As a leader in our industry since 2000, we continually invest in research to demonstrate the benefits of our products for your health. So far, three independent clinical studies have scientifically demonstrated that AminoLock® Collagen reduces joint pain associated with osteoarthritis. In addition, we work closely with McGill University to expand our knowledge of the benefits of our proprietary ingredient.

Claude has more than 28 years of experience in the pharmaceutical industry, in Europe and Canada, with a solid foundation of university studies in Pharmacy (bachelor), Nutrition, Functional Food, Health (Master) and Regulatory Affairs (Certificate).

Her values are based on Honesty, Transparency and Humanity. Passionate and dedicated, her vision allows the Genacol Research and Development’s Department to create great projects and safe, reliable and effective quality products.

Her goals are to, properly and truly, serve and satisfy the customers by helping them manage their health and wellness needs. She continually seeks to demonstrate new preventive approaches for chronic diseases, in light of recent knowledge and scientific discovery on the role and place of nutraceuticals, functional foods and natural health products in the maintenance of good health.

The first study was conducted over a six-month period at the University of Liège and included 200 subjects, aged 50 and over, who suffered from joint pain. The objective of the study was to demonstrate the efficacy of AminoLock® Collagen (1200 mg) in relieving joint pain, as compared to a placebo.

Results: Patients who were given AminoLock® Collagen instead of a placebo obtained better scores on the VAS, a scale used to measure pain levels. The results demonstrated AminoLock® Collagen’s superior efficacy in relieving joint pain.

The second study was conducted at Veterans Memorial Medical Centre in the Philippines.

The objective of the study was to demonstrate the efficacy of AminoLock® Collagen in relieving knee osteoarthritis pain, as compared to a nonsteroidal anti-inflammatory drug. The study was conducted over a six-month period and included 113 patients.

Result: After 6 months of treatment, patients who were given AminoLock® Collagen reported a statistically significant reduction in pain, while the group given the anti-inflammatory drug reported no significant difference with respect to their pain levels.

The third clinical study was conducted at the University of Santo Tomas Hospital in the Philippines.

The objective of the study was to determine the efficacy of AminoLock® Collagen, combined with physical exercise, in treating osteoarthritis of the knee. The placebo-controlled triple-blind study included 109 subjects, aged 50 and over, who had experienced knee pain for over a month.

Results: The study demonstrated that AminoLock® Collagen, combined with exercise, relieves pain, improves general joint function, and produces intra-articular and periarticular structural changes., an independent organization that evaluates nutritional products in the USA, recognized Genacol®’s clinical study as: ONE OF THE LARGEST STUDIES ON COLLAGEN HYDROLYZATES.

The report also mentions that after 6 months of taking AminoLock® Collagen (Genacol), most of the participants reported a reduction in pain (Bruyère, Comp Ther Med 2012)

Click here to access the report